1WorldWide Antimalarial Resistance Network (WWARN), Oxford, United Kingdom.
2Infectious Diseases Data Observatory (IDDO), Oxford, United Kingdom.
Am J Trop Med Hyg. 2020 Jul;103(1):359-368. doi: 10.4269/ajtmh.19-0706. Epub 2020 May 7.
Parasite resistance to antimalarial drugs poses a serious threat to malaria control. The WorldWide Antimalarial Resistance Network (WWARN) aims to provide a collaborative platform to support the global malaria research effort. Here, we describe the "WWARN clinical trials publication library," an open-access, up-to-date resource to streamline the synthesis of antimalarial safety and efficacy data. A series of iteratively refined database searches were conducted to identify prospective clinical trials assessing antimalarial drug efficacy with at least 28 days of follow-up. Of approximately 45,000 articles screened, 1,221 trials published between 1946 and 2018 were identified, representing 2,339 treatment arms and 323,819 patients. In trials from endemic locations, 75.7% (787/1,040) recruited patients with , 17.0% (177/1,040) , 6.9% (72/1,040) both, and 0.4% (4/1,040) other species; 57.2% (585/1,022) of trials included under-fives and 5.3% (55/1,036) included pregnant women. In Africa, there has been a marked increase in both and studies over the last two decades. The WHO-recommended artemisinin-based combination therapies alone or with a gametocidal drug were assessed in 39.5% (705/1,783) of treatment arms and 10.5% (45/429) of arms, increasing to 78.0% (266/341) and 22.9% (27/118), respectively, in the last five years. The library is a comprehensive, open-access tool that can be used by the malaria community to explore the collective knowledge on antimalarial efficacy (available at https://www.wwarn.org/tools-resources/literature-reviews/wwarn-clinical-trials-publication-library). It is the first of its kind in the field of global infectious diseases, and lessons learnt in its creation can be adapted to other infectious diseases.
寄生虫对抗疟药物的耐药性对疟疾控制构成严重威胁。全球抗疟耐药网络 (WWARN) 旨在提供一个协作平台，以支持全球疟疾研究工作。在这里，我们描述了“WWARN 临床试验出版物库”，这是一个开放获取的最新资源，可以简化抗疟安全性和疗效数据的综合分析。我们进行了一系列迭代式的数据库搜索，以确定具有至少 28 天随访的评估抗疟药物疗效的前瞻性临床试验。在筛选出的大约 45000 篇文章中，确定了 1946 年至 2018 年期间发表的 1221 项试验，这些试验代表了 2339 个治疗组和 323819 名患者。在来自流行地区的试验中，75.7%（787/1040）招募了患有 的患者，17.0%（177/1040）招募了患有 的患者，6.9%（72/1040）招募了同时患有 和 的患者，0.4%（4/1040）招募了患有其他 的患者；57.2%（585/1022）的试验纳入了五岁以下儿童，5.3%（55/1036）的试验纳入了孕妇。在过去的二十年中，非洲地区 和 的研究数量明显增加。单独使用世卫组织推荐的青蒿素为基础的联合疗法或联合配子杀灭药物进行评估的治疗组占 39.5%（705/1783）， 治疗组占 10.5%（45/429），在过去五年中，这一比例分别增加到 78.0%（266/341）和 22.9%（27/118）。该文库是一个全面的、开放获取的工具，可以供疟疾社区用来探索有关抗疟疗效的集体知识（可在 https://www.wwarn.org/tools-resources/literature-reviews/wwarn-clinical-trials-publication-library 上获取）。它是全球传染病领域的首创，其创建过程中的经验教训可以应用于其他传染病。
